For individuals undergoing treatment with Verzenio, access to robust support programs can significantly enhance their journey. Eli Lilly and Company, through Lilly Oncology, is committed to providing comprehensive assistance to patients prescribed oncology medications. The Verzenio Continuous Care Program stands out as a key resource, offering a range of services to support eligible patients throughout their treatment. This program, alongside the broader Lilly Oncology Support Center, aims to alleviate financial burdens and provide essential guidance.
Understanding the Lilly Oncology Support Center
The Lilly Oncology Support Center acts as a central hub for both patients and healthcare providers. It streamlines access to various support services, encompassing assistance for infused products, the Verzenio Continuous Care Program, and the Lilly Cares Foundation. This integrated approach ensures that patients receive the necessary support at every step of their treatment.
Accessing Support for Infused Products
For patients requiring infused oncology products, the Lilly Oncology Support Center offers crucial support. By enrolling, patients can benefit from benefits investigation, financial assistance, and continuous support tailored to their needs. Healthcare providers can initiate enrollment by completing the application form available on the Lilly Oncology Support Center website and faxing it to the designated number.
Deep Dive into the Verzenio Continuous Care Program
The Verzenio Continuous Care Program is specifically designed to provide ongoing support for patients prescribed Verzenio (abemaciclib). This comprehensive program encompasses several key components:
- Benefits Investigation Support: Navigating insurance coverage and understanding the financial aspects of treatment can be complex. The program offers assistance in investigating patient benefits to clarify coverage details and potential out-of-pocket costs.
- MyRightDose Program: Maintaining consistent treatment with the appropriate dosage is crucial for optimal outcomes. The Verzenio MyRightDose Program ensures that eligible patients can continue their Verzenio therapy without interruption due to dosage adjustments. This program facilitates timely delivery of Verzenio directly to patients, often within 48 hours of enrollment. Eligibility criteria include being 18 years or older, residing in the United States or Puerto Rico, possessing a valid Verzenio prescription for an FDA-approved indication, and returning any unused pills as instructed. Further details and enrollment forms are available on the Verzenio website, and the program can be contacted directly for inquiries.
- Companion in Care Program: Emotional and informational support plays a vital role in the patient experience. Once enrolled in the Verzenio Continuous Care Program, patients gain access to the Companion in Care Program. This personalized service connects patients with a dedicated point of contact who provides consistent support throughout their treatment journey. The companion can assist in clarifying treatment expectations, offering emotional encouragement, addressing questions about side effects, and guiding patients back to their healthcare practice for medical advice when necessary.
- Other Support Services: Beyond these core components, the Verzenio Continuous Care Program may offer additional support services to address the diverse needs of patients undergoing Verzenio treatment.
Eligibility and Enrollment in the Verzenio Continuous Care Program
To be eligible for the Verzenio Continuous Care Program, patients must be at least 18 years of age, have a prescription for Verzenio for an FDA-approved indication, and meet specific eligibility requirements. Healthcare providers can initiate the enrollment process for their patients by completing the application form available on the Verzenio website and faxing it to the provided number.
Lilly Cares Foundation: Patient Assistance for the Uninsured and Underinsured
For patients facing financial hardship, the Lilly Cares Foundation provides a crucial safety net. This Patient Assistance Program is designed to support uninsured or underinsured patients who have been prescribed Lilly Oncology medications. Eligibility criteria include permanent legal residency in the United States, Puerto Rico, or the US Virgin Islands; a prescription for a qualifying Lilly medication; lack of insurance or enrollment in Medicare Part D only; and not being enrolled in or denied Medicaid, full Low Income Subsidy (LIS), or Veterans (VA) Benefits (with specific exceptions for Humatrope patients). Patients must also meet household income guidelines to qualify. Detailed information and resources are available on the Lilly Cares Foundation website.
Conclusion
The Verzenio Continuous Care Program, in conjunction with the Lilly Oncology Support Center and the Lilly Cares Foundation, represents Eli Lilly’s commitment to holistic patient support. By providing financial assistance, medication access programs like MyRightDose, and personalized support through the Companion in Care Program, these initiatives aim to empower patients throughout their Verzenio treatment journey and beyond. Healthcare providers are encouraged to explore these resources to ensure their patients receive the comprehensive support they deserve.
